Crystalline forms of an integrin receptor antagonist
摘要
The present invention relates to novel crystalline forms of the integrin alphavbeta3 antagonist 3-{2-oxo-3-[3-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-propyl]imidazolidin-1-yl}-3(S)-(6-methoxy-pyridin-3-yl)-propionic acid.